Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype
Vancouver, British Columbia (PRWEB) April 20, 2015 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF), developer of a hand-held Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report the release of the first publicly available images of its marijuana breathalyzer Alpha prototype and an updated video presentation of its Cannabix Marijuana Breathalyzer. Media files and video that show the design and features of the prototype are available for online viewing at cannabixtechnologies.com.
The Alpha prototype images will also be showcased at the Marijuana Investor Summit and Business Expo (http://www.marijuanainvestorsummit.com) on April 21-22, 2015 in Denver, Colorado, at Booth 308. The Alpha device testing is well underway with medical marijuana users. The objective of the testing is to maximize THC sensitivity, detection and reliability of the device for use as a roadside or workplace drug impairment tool. The Company is developing a Beta version for trial testing with external organizations.
Kal Malhi, President of Cannabix Technologies stated, “We have made good progress with our internal testing of the Alpha version of the marijuana breathalyzer prototype. In particular, we have been working to optimize breath flow mechanics in the device by testing a range of different materials and air chamber designs. There have been significant changes in the look and design of the device since our first engineered renderings; we expect this to continue as we work on developing our Beta version. We look forward to meeting investors, media, government officials and industry participants in Denver.”
For more information visit cannabixtechnologies.com
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. The device is currently in prototype development.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built, work successfully or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Scott Ledingham, PRmediaNow, +1 (613) 806-7135, [email protected]
Share this article